Inventor · disambiguated record
Seth Cabot Hopkins
Also filed as: HOPKINS SETH · HOPKINS SETH C · HOPKINS SETH CABOT
22 granted patents·17 pending applications·211 citations·filing 2003–2025
95Inventor score
Top patents by PatentIndex Score
39 records- 0197US10874639B2Nonracemic mixtures and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2020·Granted Dec 29, 2020·8 cites·30 claims
- 0297US10660875B1Nonracemic mixtures and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2020·Granted May 26, 2020·10 cites·24 claims
- 0395US10369134B2Nonracemic mixtures and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2018·Granted Aug 6, 2019·14 cites·29 claims
- 0494US10576058B2Nonracemic mixtures and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2019·Granted Mar 3, 2020·10 cites·6 claims
- 0594US7615572B2Pyrrole and pyrazole DAAO inhibitorsSEPRACOR INC·Filed 2008·Granted Nov 10, 2009·26 cites·8 claims
- 0693US11517558B2Nonracemic mixtures and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2020·Granted Dec 6, 2022·2 cites·20 claims
- 0793US7579370B2Fused heterocyclesSEPRACOR INC·Filed 2007·Granted Aug 25, 2009·25 cites·15 claims
- 0892US11654113B2Modified release formulations and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2021·Granted May 23, 2023·3 cites·24 claims
- 0992US11160758B2Modified release formulations and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2020·Granted Nov 2, 2021·6 cites·29 claims
- 1091US7166725B2Benzo[d]isoxazol-3-ol DAAO inhibitorsSEPRACOR INC·Filed 2004·Granted Jan 23, 2007·47 cites·3 claims
- 1189US11129807B2Methods of treating schizophreniaSUNOVION PHARMACEUTICALS INC·Filed 2018·Granted Sep 28, 2021·5 cites·22 claims
- 1289US7884124B2Fluoro-substituted inhibitors of D-amino acid oxidaseSEPRACOR INC·Filed 2007·Granted Feb 8, 2011·9 cites·30 claims
- 1389US7488747B2Pyrrole and pyrazole DAAO inhibitorsSEPRACOR INC·Filed 2004·Granted Feb 10, 2009·28 cites·8 claims
- 1485US7893098B2Pyrrole and pyrazole DAAO inhibitorsSEPRACOR INC·Filed 2009·Granted Feb 22, 2011·6 cites·10 claims
- 1584US12161623B2Nonracemic mixtures and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2022·Granted Dec 10, 2024·0 cites·15 claims
- 1684US7902252B2Inhibitors of D-amino acid oxidaseSEPRACOR INC·Filed 2009·Granted Mar 8, 2011·4 cites·12 claims
- 1781US11738002B2Methods of treating neurological and psychiatric disordersSUNOVION PHARMACEUTICALS INC·Filed 2021·Granted Aug 29, 2023·1 cites·21 claims
- 1877US7511073B2Amines that inhibit a mammalian anandamide transporter, and methods of use thereofSEPRACOR INC·Filed 2006·Granted Mar 31, 2009·2 cites·10 claims
- 1975US12161758B2Modified release formulations and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2023·Granted Dec 10, 2024·0 cites·34 claims
- 2073US7049329B2Amines that inhibit a mammalian anandamide transporter, and methods of use thereofSEPRACOR INC·Filed 2003·Granted May 23, 2006·5 cites·16 claims
- 2173US2024350453A1Methods of treating neurological and psychiatric disordersSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 2270US2025057806A1Methods of treating schizophreniaSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 2364US7671087B2Amines that inhibit a mammalian anandamide transporter, and methods of use thereofSEPRACOR INC·Filed 2009·Granted Mar 2, 2010·0 cites·16 claims
- 2464US2010029741A1Fused heterocyclesSEPRACOR INC·Filed 2009·Application pending·0 cites
- 2564US2022062229A1Methods of treating schizophreniaSUNOVION PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2664US2010022612A1Fused heterocyclesSEPRACOR INC·Filed 2009·Application pending·0 cites
- 2763US2025312308A1Methods of treating neurological and psychiatric disordersSUMITOMO PHARMA AMERICA INC·Filed 2025·Application pending·0 cites
- 2862US2024185965A1Computational Model and Methods for Selecting Clinical Trial Subjects to Reduce HeterogeneitySUNOVION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2960US2024366559A1Methods of treating neurological and psychiatric disordersSUMITOMO PHARMA AMERICA INC·Filed 2024·Application pending·0 cites
- 3060US2020179336A1Methods of treating neurological and psychiatric disordersSUNOVION PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3155US8497278B2Imidazo[1,2-a]pyridine compoundsFANG QUN KEVIN·Filed 2009·Granted Jul 30, 2013·0 cites·10 claims
- 3255US2023241024A1Methods of treating metabolic disordersSUNOVION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3353US2025262185A1Methods of administering neuropsychiatric medications based on renal impairmentSUMITOMO PHARMA AMERICA INC·Filed 2025·Application pending·0 cites
- 3453US2011092559A1Pyrrole and pyrazole daao inhibitorsSUNOVION PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 3551US2013289013A1IMIDAZO[1,2-a]PYRIDINE COMPOUNDSSUNOVION PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3650US2008058395A1Fused heterocyclic inhibitors of D-amino acid oxidaseSEPRACOR INC·Filed 2007·Application pending·0 cites
- 3748US2022323409A1Modified release formulations and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3848US2009099248A1Inhibitors of d-amino acid oxidaseSEPRACOR INC·Filed 2008·Application pending·0 cites
- 3947US2008175903A1Treatment of anxiety with eszopicloneSEPRACOR INC·Filed 2007·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →